RxDoctor Payments Data

Madelynn Randall

Nurse Practitioner · Layton, UTNPI 1700660065

Payments from drug & device makers

$1,612in general payments, 2019–2025

Across 37 payments — averaging $43.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • AbbVie$146
  • Averitas Pharma Inc.$90
  • Collegium Pharmaceutical, Inc.$85
  • Nalu Medical, Inc.$68
  • Nevro Corp.$52
  • plus $123 from 5 others

What the payments were for

  • Travel & lodging$52933%
  • Food & beverage$1,08267%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,612 in reported general payments places this provider in the 80th percentile of 979 nurse practitioner providers in Utah.

See all nurse practitioner providers in Utah

Medicare billing

Part B allowed, 2024
$40,696
Medicare patients
125
Services billed
2,937

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nucynta ErTapentadol Hcl24$25,914
BelbucaBuprenorphine Hcl13$12,621
Fentanyl18$3,133
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen44$1,711
Pregabalin56$1,554
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen61$1,391
Gabapentin77$812
Hydromorphone Hcl23$781
Tramadol Hcl89$715
Tizanidine Hcl40$615
Methocarbamol12$256
Celecoxib25$195
Morphine Sulfate ErMorphine Sulfate11$194
Cyclobenzaprine Hcl23$186
Diazepam59$56

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta Er, Belbuca$85$38,53537 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 979 nurse practitioner providers in Utah.

Other nurse practitioner in Layton

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →